Fundació Investigació Sanitària Illes Balears (FISIB), Ciber Enfermedades Respiratorias (CIBERES), Barcelona, Catalunya, Spain.
GlaxoSmithKline Research and Development, King of Prussia, Pennsylvania, USA.
Thorax. 2014 Jul;69(7):666-72. doi: 10.1136/thoraxjnl-2013-204778. Epub 2013 Dec 5.
The Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study was a large 3-year observational controlled multicentre international study aimed at defining clinically relevant subtypes of chronic obstructive pulmonary disease (COPD) and identifying novel biomarkers and genetic factors. So far, the ECLIPSE study has produced more than 50 original publications and 75 communications to international meetings, many of which have significantly influenced our understanding of COPD. However, because there is not one paper reporting the biomarker results of the ECLIPSE study that may serve as a reference for practising clinicians, researchers and healthcare providers from academia, industry and government agencies interested in COPD, we decided to write a review summarising the main biomarker findings in ECLIPSE.
ECLIPSE 研究旨在确定慢性阻塞性肺疾病(COPD)的临床相关亚型,并识别新型生物标志物和遗传因素,这是一项为期 3 年的大型观察性对照多中心国际研究。到目前为止,ECLIPSE 研究已经产生了 50 多篇原始出版物和 75 篇国际会议交流文章,其中许多都极大地影响了我们对 COPD 的认识。然而,由于没有一篇论文报告 ECLIPSE 研究的生物标志物结果,因此无法为临床医生、学者、工业界和政府机构的研究人员和医疗保健提供者提供参考,我们决定写一篇综述,总结 ECLIPSE 中的主要生物标志物研究结果。